There is a current controversy in the literature about the mechanism of the hypotensive
action of the new 5-hydroxytryptamine antagonist, ketanserin. The advocates of the drug …

The mechanism of the hypotensive action of ketanserin, a selective 5-HT2 receptor
antagonist with appreciable affinity for [alpha] 1-adrenoceptors, has been investigated. In …

Ketanserin, a new 5‐hydroxy‐tryptamine antagonist, was given at three different dosage
levels (double‐blind, randomized) in a dose finding study for 2 months to 31 patients with …

Ketanserin is a selective antagonist of serotonergic receptors, but it also possesses alpha-i
adrenolytic activity. The present study in rats was designed to establish whether the …

Abstract Serotonin (5-hydroxytryptamine; also called 5-HT) modifies cardiovascular activity
by central as well as peripheral sites of action. When 5-HT is injected within the central …

1. In a double-blind placebo-controlled crossover study a 4 week treatment with ketanserin
was shown to reduce systolic and diastolic blood pressure markedly and significantly in 10 …

1 The abilities of ketanserin, ritanserin, R56413 and LY53857 to inhibit 5‐hydroxytryptamine
(5‐HT) and noradrenaline‐induced vasoconstrictor responses both in vitro and in vivo and …

The antihypertensive mode of action of the 5HT2 receptor antagonist, ketanserin (KET), is
still a subject of controversy and has been evaluated predominantly in acute studies. Acute …

The serotonergic receptor antagonist 3-(2-[4-(4-fluorobenzoyl)-1-piperidinyl] ethyl)-2, 4-[1H,
3H] quinazolinedione (ketanserin) causes dose-dependent inhibition of the effects of 5 …

Following intravenous administration of ketanserin (0.3–10 mg kg− 1) to conscious or
anaesthetized normotensive and spontaneously hypertensive rats there were dose …